Pfizer and Eisai Commence Co-promotion of Nurtec for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine – Eisai + Pfizer

Pfizer Japan Inc. and Eisai Co., Ltd. announced that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec OD Tablet 75mg (generic name: rimegepant sulfate hydrate) in Japan from September 1, 2026.
Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in the treatment of migraine. Both companies will provide appropriate use information to medical institutions in Japan, while Pfizer remains responsible for the development, manufacturing, distribution, and commercialization of Nurtec. Through this collaboration, Pfizer, the marketing authorization holder, and Eisai, which positions neurology as a strategic focus area, will leverage their respective expertise and healthcare networks to further strengthen the provision of information and promote the appropriate use of Nurtec.